Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Forest Laboratories
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ambulatory male or female patients at least 50 years of age (females at least 2 years postmenopausal)
A diagnosis of probable AD \[according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) criteria\] of moderate severity \[Mini-Mental State Examination score between 15 and 20, inclusive\]
On a stable dose of Food and Drug Administration (FDA)-approved acetylcholinesterase inhibitor
You may not be if
Current Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) Axis I disorder other than AD
Previous imaging results not consistent with the diagnosis of AD
Modified Hachinski Ischemia Score greater than 4
Evidence of other neurologic disorders
Inability to participate in MRI testing
No clinically significant systemic disease
A known or suspected history of alcohol or drug abuse in the past 10 years
